Australia’s CSL eyes COVID-19 vaccine by mid-2021 as it beats profit forecast

16Views

August 19, 2020

SYDNEY Australian biotech giant CSL Ltd raised hopes on Wednesday of delivering a coronavirus vaccine within a year as annual profit outstripped a forecast, thanks to heavy demand for inoculation and blood plasma products that sent shares soaring.

The update from one of Australia’s biggest listed companies puts the spotlight on the former government laboratory that has joined several global projects to develop a vaccine but has been cautious about setting a timeline.

One project is a partnership with Australia’s University of Queensland, and “We now estimate first doses of the UQ vaccine will be available for … emergency use by the middle of 2021”, CSL’s Chief Executive Paul Perreault told a news teleconference.

CSL has said it could make the first large-scale doses of the vaccine at its Melbourne facility. The first trial doses were administered in July, and the company says it will manage subsequent trial phases.

Optimism over the company’s prospects and a better-than-expected annual profit pushed its shares up 7% by mid-afternoon, outperforming a rise of 0.8% in the benchmark.

“Demand for products, as seen in the robust FY20 result, remains strong and while there is earnings pressure in FY21, the longer-term story remains intact,” Credit Suisse analysts said in a note.

For the year to the end of June, the company reported net profit of $2.25 billion on a constant currency basis, up from $1.92 billion a year earlier and bettering the figure of $2.17 billion at the top end of its April guidance.

The constant currency profit strips out the impact of foreign exchange changes over the year.

The company upped its final dividend to $1.07 a share, from $1.00 a year earlier.

For the current financial year it forecast comparable net profit in a range from $2.1 billion to $2.27 billion, reflecting nearly flat growth because of difficulty securing blood donations for plasma products amid virus curbs.

The company is also in talks with AstraZeneca to make the British drugmaker’s potential vaccine in Australia, but Perreault said only that its capabilities were in focus.

Also Watch

Sushant Death Probe: SC Upholds Patna Police FIR In Setback For Rhea & Mumbai Police | CNN News18

“We’re certainly in discussions with AZ and the Australian government about what is our ability to do more,” he added.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Array
(
[videos] => Array
(
[0] => Array
(
[id] => 5f3cc88d082aa874143e1f24
[youtube_id] => yomkunxPk_w
Australia’s CSL eyes COVID-19 vaccine by mid-2021 as it beats profit forecast => Sushant Death Probe: SC Upholds Patna Police FIR In Setback For Rhea & Mumbai Police | CNN News18
)

[1] => Array
(
[id] => 5f3cc762082aa874143e1ee5
[youtube_id] => oK8ggOiIlrU
Australia’s CSL eyes COVID-19 vaccine by mid-2021 as it beats profit forecast => Bihar DGP On CBI Probe In SSR Case: I’m Very Happy With SC Verdict, Hopeful Sushant Will Get Justice
)

)

[query] => https://pubstack.nw18.com/pubsync/v1/api/videos/recommended?source=n18english&channels=5d95e6c378c2f2492e2148a2,5d95e6c278c2f2492e214884,5d96f74de3f5f312274ca307&categories=5d95e6d7340a9e4981b2e10a&publish_min=2020-08-16T12:12:08.000Z&publish_max=2020-08-19T12:12:08.000Z&sort_by=date-relevance&order_by=0&limit=2
)

Australia’s CSL eyes COVID-19 vaccine by mid-2021 as it beats profit forecast

Also Watch

Speak Your Mind

LEAVE A REPLY Cancel reply

Get in Touch

Recommend for You

Oh hi there It’s nice to meet you.

Subscribe and receive our weekly newsletter packed with awesome articles that really matters to you!

You might also like

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

About Us

Follow Us

Support Us & Be a Patreon

Add QNewsHub to your Homescreen!

Oh hi there
It’s nice to meet you.